JP7454292B2 - 腎臓結石及び腎臓結石片を磁化するための調合液、並びに腎臓結石及び腎臓結石片を除去するためのキット。 - Google Patents
腎臓結石及び腎臓結石片を磁化するための調合液、並びに腎臓結石及び腎臓結石片を除去するためのキット。 Download PDFInfo
- Publication number
- JP7454292B2 JP7454292B2 JP2022552845A JP2022552845A JP7454292B2 JP 7454292 B2 JP7454292 B2 JP 7454292B2 JP 2022552845 A JP2022552845 A JP 2022552845A JP 2022552845 A JP2022552845 A JP 2022552845A JP 7454292 B2 JP7454292 B2 JP 7454292B2
- Authority
- JP
- Japan
- Prior art keywords
- preparation
- kidney
- formulation
- magnetic particles
- stones
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 208000000913 Kidney Calculi Diseases 0.000 title claims description 73
- 206010029148 Nephrolithiasis Diseases 0.000 title claims description 73
- 238000002360 preparation method Methods 0.000 title claims description 34
- 239000012634 fragment Substances 0.000 title claims description 21
- 239000006249 magnetic particle Substances 0.000 claims description 45
- 239000000203 mixture Substances 0.000 claims description 44
- 238000009472 formulation Methods 0.000 claims description 32
- 239000002245 particle Substances 0.000 claims description 21
- 150000003839 salts Chemical class 0.000 claims description 21
- 239000007788 liquid Substances 0.000 claims description 15
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims description 14
- 230000005291 magnetic effect Effects 0.000 claims description 13
- PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 claims description 9
- 239000002904 solvent Substances 0.000 claims description 8
- 239000011164 primary particle Substances 0.000 claims description 7
- 229910001566 austenite Inorganic materials 0.000 claims description 6
- 229920006037 cross link polymer Polymers 0.000 claims description 6
- 229910052759 nickel Inorganic materials 0.000 claims description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 6
- 229920000642 polymer Polymers 0.000 claims description 5
- 239000000725 suspension Substances 0.000 claims description 5
- 229910052749 magnesium Inorganic materials 0.000 claims description 4
- 239000000243 solution Substances 0.000 claims description 4
- 229910000859 α-Fe Inorganic materials 0.000 claims description 4
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 claims description 3
- 229910000828 alnico Inorganic materials 0.000 claims description 3
- 229910052791 calcium Inorganic materials 0.000 claims description 3
- 150000001805 chlorine compounds Chemical class 0.000 claims description 3
- 229910017052 cobalt Inorganic materials 0.000 claims description 3
- 239000010941 cobalt Substances 0.000 claims description 3
- GUTLYIVDDKVIGB-UHFFFAOYSA-N cobalt atom Chemical compound [Co] GUTLYIVDDKVIGB-UHFFFAOYSA-N 0.000 claims description 3
- 239000006185 dispersion Substances 0.000 claims description 3
- 229910052744 lithium Inorganic materials 0.000 claims description 3
- VLTRZXGMWDSKGL-UHFFFAOYSA-N perchloric acid Chemical class OCl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-N 0.000 claims description 3
- 229910052700 potassium Inorganic materials 0.000 claims description 3
- 102000004169 proteins and genes Human genes 0.000 claims description 3
- 108090000623 proteins and genes Proteins 0.000 claims description 3
- 229910000938 samarium–cobalt magnet Inorganic materials 0.000 claims description 3
- 229910052708 sodium Inorganic materials 0.000 claims description 3
- 229910019142 PO4 Inorganic materials 0.000 claims description 2
- 230000005294 ferromagnetic effect Effects 0.000 claims description 2
- 229910052742 iron Inorganic materials 0.000 claims description 2
- 235000021317 phosphate Nutrition 0.000 claims description 2
- 150000003013 phosphoric acid derivatives Chemical class 0.000 claims description 2
- 150000001298 alcohols Chemical class 0.000 claims 1
- 235000002639 sodium chloride Nutrition 0.000 description 28
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 26
- 210000003734 kidney Anatomy 0.000 description 17
- 239000011780 sodium chloride Substances 0.000 description 13
- 230000002776 aggregation Effects 0.000 description 8
- 230000003993 interaction Effects 0.000 description 7
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 6
- 238000004220 aggregation Methods 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 5
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 4
- KWGKDLIKAYFUFQ-UHFFFAOYSA-M lithium chloride Chemical compound [Li+].[Cl-] KWGKDLIKAYFUFQ-UHFFFAOYSA-M 0.000 description 4
- 239000011777 magnesium Substances 0.000 description 4
- 238000004438 BET method Methods 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 238000002441 X-ray diffraction Methods 0.000 description 3
- 239000011575 calcium Substances 0.000 description 3
- 239000003431 cross linking reagent Substances 0.000 description 3
- 238000010586 diagram Methods 0.000 description 3
- UQSXHKLRYXJYBZ-UHFFFAOYSA-N iron oxide Inorganic materials [Fe]=O UQSXHKLRYXJYBZ-UHFFFAOYSA-N 0.000 description 3
- 230000005415 magnetization Effects 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 229910052757 nitrogen Inorganic materials 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- 239000004575 stone Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 238000005054 agglomeration Methods 0.000 description 2
- 230000005540 biological transmission Effects 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 239000008394 flocculating agent Substances 0.000 description 2
- 235000013980 iron oxide Nutrition 0.000 description 2
- RBTARNINKXHZNM-UHFFFAOYSA-K iron trichloride Chemical compound Cl[Fe](Cl)Cl RBTARNINKXHZNM-UHFFFAOYSA-K 0.000 description 2
- SZVJSHCCFOBDDC-UHFFFAOYSA-N iron(II,III) oxide Inorganic materials O=[Fe]O[Fe]O[Fe]=O SZVJSHCCFOBDDC-UHFFFAOYSA-N 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 235000011164 potassium chloride Nutrition 0.000 description 2
- 238000001179 sorption measurement Methods 0.000 description 2
- 229910052567 struvite Inorganic materials 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- YPFNIPKMNMDDDB-UHFFFAOYSA-K 2-[2-[bis(carboxylatomethyl)amino]ethyl-(2-hydroxyethyl)amino]acetate;iron(3+) Chemical compound [Fe+3].OCCN(CC([O-])=O)CCN(CC([O-])=O)CC([O-])=O YPFNIPKMNMDDDB-UHFFFAOYSA-K 0.000 description 1
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 102000016938 Catalase Human genes 0.000 description 1
- 108010053835 Catalase Proteins 0.000 description 1
- 239000004971 Cross linker Substances 0.000 description 1
- 238000005169 Debye-Scherrer Methods 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 229910021577 Iron(II) chloride Inorganic materials 0.000 description 1
- 229910021578 Iron(III) chloride Inorganic materials 0.000 description 1
- 206010023435 Kidney small Diseases 0.000 description 1
- LEVWYRKDKASIDU-IMJSIDKUSA-N L-cystine Chemical compound [O-]C(=O)[C@@H]([NH3+])CSSC[C@H]([NH3+])C([O-])=O LEVWYRKDKASIDU-IMJSIDKUSA-N 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- PPWHTZKZQNXVAE-UHFFFAOYSA-N Tetracaine hydrochloride Chemical compound Cl.CCCCNC1=CC=C(C(=O)OCCN(C)C)C=C1 PPWHTZKZQNXVAE-UHFFFAOYSA-N 0.000 description 1
- 208000009911 Urinary Calculi Diseases 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 235000019270 ammonium chloride Nutrition 0.000 description 1
- MXZRMHIULZDAKC-UHFFFAOYSA-L ammonium magnesium phosphate Chemical compound [NH4+].[Mg+2].[O-]P([O-])([O-])=O MXZRMHIULZDAKC-UHFFFAOYSA-L 0.000 description 1
- CKMXBZGNNVIXHC-UHFFFAOYSA-L ammonium magnesium phosphate hexahydrate Chemical compound [NH4+].O.O.O.O.O.O.[Mg+2].[O-]P([O-])([O-])=O CKMXBZGNNVIXHC-UHFFFAOYSA-L 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 229910052788 barium Inorganic materials 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 235000011148 calcium chloride Nutrition 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- QXDMQSPYEZFLGF-UHFFFAOYSA-L calcium oxalate Chemical compound [Ca+2].[O-]C(=O)C([O-])=O QXDMQSPYEZFLGF-UHFFFAOYSA-L 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 238000000975 co-precipitation Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 229960003067 cystine Drugs 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 230000009881 electrostatic interaction Effects 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 239000001307 helium Substances 0.000 description 1
- 229910052734 helium Inorganic materials 0.000 description 1
- SWQJXJOGLNCZEY-UHFFFAOYSA-N helium atom Chemical compound [He] SWQJXJOGLNCZEY-UHFFFAOYSA-N 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 230000009610 hypersensitivity Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- NMCUIPGRVMDVDB-UHFFFAOYSA-L iron dichloride Chemical compound Cl[Fe]Cl NMCUIPGRVMDVDB-UHFFFAOYSA-L 0.000 description 1
- VBMVTYDPPZVILR-UHFFFAOYSA-N iron(2+);oxygen(2-) Chemical class [O-2].[Fe+2] VBMVTYDPPZVILR-UHFFFAOYSA-N 0.000 description 1
- JEIPFZHSYJVQDO-UHFFFAOYSA-N iron(III) oxide Inorganic materials O=[Fe]O[Fe]=O JEIPFZHSYJVQDO-UHFFFAOYSA-N 0.000 description 1
- 239000012669 liquid formulation Substances 0.000 description 1
- 235000011147 magnesium chloride Nutrition 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 229910052748 manganese Inorganic materials 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 229910044991 metal oxide Inorganic materials 0.000 description 1
- 150000004706 metal oxides Chemical class 0.000 description 1
- 239000002923 metal particle Substances 0.000 description 1
- 239000002105 nanoparticle Substances 0.000 description 1
- 229910001172 neodymium magnet Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 235000011121 sodium hydroxide Nutrition 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 229910052712 strontium Inorganic materials 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000563 toxic property Toxicity 0.000 description 1
- 238000004627 transmission electron microscopy Methods 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 210000000626 ureter Anatomy 0.000 description 1
- 210000001635 urinary tract Anatomy 0.000 description 1
- 208000008281 urolithiasis Diseases 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
- A61K9/0009—Galenical forms characterised by the drug release technique; Application systems commanded by energy involving or responsive to electricity, magnetism or acoustic waves; Galenical aspects of sonophoresis, iontophoresis, electroporation or electroosmosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/26—Iron; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/14—Alkali metal chlorides; Alkaline earth metal chlorides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/42—Phosphorus; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Inorganic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Dispersion Chemistry (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Urology & Nephrology (AREA)
- Surgery (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Soft Magnetic Materials (AREA)
- Materials For Medical Uses (AREA)
- Water Treatment By Electricity Or Magnetism (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Hard Magnetic Materials (AREA)
Description
図1は、本発明の一実施形態による調合液を示す概略図である;
図2は、図1の調合液で処理した腎臓結石の概略断面図である;そして、
図3は、磁性粒子の流体力学的直径をNaClの濃度の関数として示す図である。
2 容器
3 磁性粒子
4 塩
5 溶媒
10 腎臓結石
Claims (20)
- 腎臓結石(10)又は腎臓結石片を磁化するための調合液(1)であって、
- 磁性粒子(3);
- Li、Na、K、アンモニウム、Mg及びCaの塩化物、過塩素酸塩及びリン酸塩からなる群から選択される少なくとも一つの塩(4);並びに、
- 少なくとも一つの溶媒(5)
を含み、
溶液、懸濁液又は分散液の形態である、調合液(1)。 - 磁性粒子(3)が強磁性粒子である、請求項1に記載の調合液(1)。
- 磁性粒子(3)が鉄、ニッケル、コバルト、AlNiCo、SmCo、Nd 2 Fe 14 B、Ni 80 Fe 20 、NiFeCo、フェライト、Fe 3 O 4 、γ-Fe 2 O 3 、Fe 3 O 4 とγ-Fe 2 O 3 の混合相、及びこれらの混合物から選択される、請求項1に記載の調合液(1)。
- 磁性粒子(3)が、2~100nmの一次粒径を有する、請求項1~3のいずれか一項に記載の調合液(1)。
- 磁性粒子(3)が、4~20nmの一次粒径を有する、請求項1~3のいずれか一項に記載の調合液(1)。
- 磁性粒子(3)が、5~15nmの一次粒径を有する、請求項1~3のいずれか一項に記載の調合液(1)。
- 磁性粒子(3)が、80~150m2/gの比表面積を有する、請求項1~6のいずれか一項に記載の調合液(1)。
- 磁性粒子(3)が、90~120m 2 /gの比表面積を有する、請求項1~6のいずれか一項に記載の調合液(1)。
- 調合液に基づく磁性粒子(3)の濃度が、2~40g/lである、請求項1~8のいずれか一項に記載の調合液(1)。
- 調合液に基づく磁性粒子(3)の濃度が、4~20g/lである、請求項1~8のいずれか一項に記載の調合液(1)。
- 調合液中の塩(4)の濃度が、少なくとも100mmolである、請求項1~10のいずれか一項に記載の調合液(1)。
- 調合液中の塩(4)の濃度が、100~2000mmolである、請求項1~10のいずれか一項に記載の調合液(1)。
- 調合液中の塩(4)の濃度が、200~1000mmolである、請求項1~10のいずれか一項に記載の調合液(1)。
- 溶媒(5)が、水、アルコール、及びそれらの混合物から選択される、請求項1~13のいずれか一項に記載の調合液(1)。
- さらに、少なくとも1つの糖及び/又は少なくとも1つのタンパク質及び/又は少なくとも1つの生理的緩衝剤をさらに含む、請求項1~14のいずれか一項に記載の調合液(1)。
- 調合液(1)のpHが、5~8の範囲である、請求項1~15のいずれか一項に記載の調合液(1)。
- 調合液(1)のpHが、6~7の範囲である、請求項1~15のいずれか一項に記載の調合液(1)。
- 調合液(1)が、皮膜形成ポリマー及び架橋ポリマーを含まない、請求項1~17のいずれか一項に記載の調合液(1)。
- 腎臓結石(10)又は腎臓結石片を除去するためのキットであって、
請求項1~18のいずれか一項に記載の調合液(1)と、調合液によって磁化された腎臓結石又は腎臓結石片を除去するための磁性器具又は磁化可能な器具とを含む、キット。 - 前記磁性器具又は磁化可能な器具は、磁石針である、請求項19に記載のキット。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP20160490.7A EP3875075B1 (de) | 2020-03-02 | 2020-03-02 | Zubereitung zur magnetisierung von nierensteinen und nierensteinfragmenten und kit zur entfernung von nierensteinen und nierensteinfragmenten |
EP20160490.7 | 2020-03-02 | ||
PCT/EP2021/054434 WO2021175660A1 (de) | 2020-03-02 | 2021-02-23 | Zubereitung zur magnetisierung von nierensteinen und nierensteinfragmenten und kit zur entfernung von nierensteinen und nierensteinfragmenten |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2023516703A JP2023516703A (ja) | 2023-04-20 |
JP7454292B2 true JP7454292B2 (ja) | 2024-03-22 |
Family
ID=69743184
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2022552845A Active JP7454292B2 (ja) | 2020-03-02 | 2021-02-23 | 腎臓結石及び腎臓結石片を磁化するための調合液、並びに腎臓結石及び腎臓結石片を除去するためのキット。 |
Country Status (8)
Country | Link |
---|---|
US (1) | US20230149450A1 (ja) |
EP (1) | EP3875075B1 (ja) |
JP (1) | JP7454292B2 (ja) |
KR (1) | KR20220143098A (ja) |
CN (1) | CN115243671A (ja) |
AU (1) | AU2021229560A1 (ja) |
CA (1) | CA3168407A1 (ja) |
WO (1) | WO2021175660A1 (ja) |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2016519957A (ja) | 2013-04-23 | 2016-07-11 | フラウンホーファー−ゲゼルシャフト・ツール・フェルデルング・デル・アンゲヴァンテン・フォルシュング・アインゲトラーゲネル・フェライン | 尿結石およびその断片を除去するためのゲル成形性系 |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2796101B1 (de) | 2013-04-23 | 2016-04-20 | Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. | Kit zum Herstellen eines vernetzten Gels zum Umschließen von Nierensteinen und/oder Nierensteinfragmenten |
KR20150078375A (ko) * | 2013-12-30 | 2015-07-08 | 한화케미칼 주식회사 | 철산화물 나노입자를 포함하는 철결핍증의 예방 또는 치료용 약학 조성물 |
-
2020
- 2020-03-02 EP EP20160490.7A patent/EP3875075B1/de active Active
-
2021
- 2021-02-23 US US17/802,655 patent/US20230149450A1/en active Pending
- 2021-02-23 CN CN202180018918.7A patent/CN115243671A/zh active Pending
- 2021-02-23 WO PCT/EP2021/054434 patent/WO2021175660A1/de active Application Filing
- 2021-02-23 JP JP2022552845A patent/JP7454292B2/ja active Active
- 2021-02-23 AU AU2021229560A patent/AU2021229560A1/en active Pending
- 2021-02-23 KR KR1020227032209A patent/KR20220143098A/ko unknown
- 2021-02-23 CA CA3168407A patent/CA3168407A1/en active Pending
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2016519957A (ja) | 2013-04-23 | 2016-07-11 | フラウンホーファー−ゲゼルシャフト・ツール・フェルデルング・デル・アンゲヴァンテン・フォルシュング・アインゲトラーゲネル・フェライン | 尿結石およびその断片を除去するためのゲル成形性系 |
Also Published As
Publication number | Publication date |
---|---|
KR20220143098A (ko) | 2022-10-24 |
CA3168407A1 (en) | 2021-09-10 |
US20230149450A1 (en) | 2023-05-18 |
WO2021175660A1 (de) | 2021-09-10 |
EP3875075B1 (de) | 2023-05-17 |
JP2023516703A (ja) | 2023-04-20 |
EP3875075A1 (de) | 2021-09-08 |
AU2021229560A1 (en) | 2022-09-01 |
CN115243671A (zh) | 2022-10-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Mahmoudi et al. | Irreversible changes in protein conformation due to interaction with superparamagnetic iron oxide nanoparticles | |
Shen et al. | One-step synthesis of monodisperse, water-soluble ultra-small Fe 3 O 4 nanoparticles for potential bio-application | |
Vatta et al. | Magnetic nanoparticles: Properties and potential applications | |
JP5765520B2 (ja) | 磁性粒子含有水分散体の製造方法 | |
JP5701408B2 (ja) | 親水性物質でコーティングされた酸化鉄ナノ粒子の調製方法、及び酸化鉄ナノ粒子を含む磁気共鳴画像造影剤 | |
US7670676B2 (en) | Pharmaceutical raw material | |
US10577254B2 (en) | Iron oxide nanoparticles doped with alkali metals or alkali earth metals capable of gigantic AC magnetic self-heating in biocompatible AC magnetic field and method of preparing the same | |
Hajdú et al. | Magnetite nanoparticles stabilized under physiological conditions for biomedical application | |
Song et al. | Highly efficient bacterial removal and disinfection by magnetic barium phosphate nanoflakes with embedded iron oxide nanoparticles | |
Liu et al. | Novel magnetic vortex nanorings/nanodiscs: Synthesis and theranostic applications | |
JP2007023027A (ja) | 磁性粒子含有医薬用原薬 | |
Marasini et al. | d‐Glucuronic Acid‐Coated Ultrasmall Paramagnetic Ln2O3 (Ln= Tb, Dy, and Ho) Nanoparticles: Magnetic Properties, Water Proton Relaxivities, and Fluorescence Properties | |
Elblbesy et al. | Bio-synthesis of magnetite nanoparticles by bacteria | |
Mokhosi et al. | Assessing the structural, morphological and magnetic properties of polymer-coated magnesium-doped cobalt ferrite (CoFe2O4) nanoparticles for biomedical application | |
JP7454292B2 (ja) | 腎臓結石及び腎臓結石片を磁化するための調合液、並びに腎臓結石及び腎臓結石片を除去するためのキット。 | |
JP5488948B2 (ja) | マグネタイト微粒子の制御方法 | |
Vaytulevich et al. | Sorbents Based on Magnetite Nanoparticles for Biomedical Applications | |
CA2931273A1 (en) | Aqueous skin care agent | |
US20180297857A1 (en) | Aqueous Synthesis of Polyhedral "Brick-Like" Iron Oxide Nanoparticles for Hyperthermia and T2 MRI Contrast Enhancement, and for Targeting Endothelial Cells for Therapeutic Delivery | |
JP4267272B2 (ja) | 生体物質の単離方法 | |
Warren | Synthesis, characterization, and functionalization of magnetic iron nanoparticles for enhanced biological applications | |
Marquina et al. | Carbon Encapsulated Functional Magnetic Nanoparticles for Life Sciences | |
Hartono et al. | Iron sand-based and ionic-based magnetic nanoparticle physical characteristics comparison for biomedical application | |
Galarreta Rodríguez | Development of Fe3-xMxO4 (M= Co and Ga) nanomaterials for biomedical applications | |
Sujita | Characterization of Magnetic Composite with Filler East Lombok Iron Sand and Polyvinyl Alcohol Matrix |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20221026 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20231003 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20231225 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20240206 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20240304 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 7454292 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |